Autoimmune Disorders Drug Delivery Devices Market by Product (Pre-filled Syringes, Pen Injectors, Vials, Auto-Injectors, Others); by Indications (Psoriasis, Multiple Sclerosis, Inflammatory Bowel Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Others); by End-Users (Hospitals & Clinics, Home Care Settings) and by Region (North America, Europe, Asia Pacific, Latin America, MEA); - Global Forecasts 2021 to 2027

Date : Oct 2021

|

Report ID : 605

|

Category : Medical Devices

|
Report Format:  PDF EXCEL PPT WORD

The Global Autoimmune Disorders Drug Delivery Devices Market Size was valued at USD 2.7 Bn in 2020 and is expected to reach USD 7.3 Bn by 2027, growing at a CAGR of 15.0% during the forecast period.

Autoimmune disease is a type of polygenic and multifactorial, which targets different organs either specifically or systematically.

Market Dynamics:

The prevalence of autoimmune diseases like rheumatoid disease is steadily increasing worldwide. Recently, many new drug delivery systems are successfully marketed to treat these diseases. However, drugs that are currently available in the market are rapidly metabolized in their free morpheme after being administered into the body, thus cleared off before getting to the target organ(s) in optimal concentrations. During the previous decade, several carrier systems in the nano-sized form are developed to take care of the sustained release of those drugs and to moderate the toxicity profile of those drugs.

Autoimmune Disorders Drug Delivery Devices Market

Technological advancement in the field of prefilled syringes is expected to boost the growth of autoimmune disorders drug delivery devices market. Rising need for biologics and biosimilar in the pharmaceutical market due to the increasing geriatric population which drives the growth of autoimmune disorders drug delivery devices market. For instance, by 2050, the world's population aged 60 years and older is expected to around 2 billion, up from 900 million in 2015 according to WHO.

However, strict legal rules and regulations might hamper the growth of targeted market during the forecast year. Moreover, providing drug delivery devices for an untapped autoimmune disorder can create an opportunity for the growth of global market. Complications associate with the devices might act as a challenge for the market of autoimmune disorder drug delivery devices.

The Global Autoimmune Disorders Drug Delivery Devices Market Segmentation:

By Product

  • Pre-filled Syringes
  • Pen Injectors
  • Vials
  • Auto-Injectors
  • Others

By Indications

  • Psoriasis
  • Multiple Sclerosis
  • Inflammatory Bowel Diseases
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Others

By End-Users

  • Hospitals & Clinics
  • Home Care Settings

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Based on product, the pre-filled syringes, is expected to dominate the global autoimmune disorders drug delivery devices market as prefilled syringes are safer and easier to use

Based on product, the global autoimmune disorders drug delivery devices market has been segmented into pre-filled syringes, pen injectors, vials, auto-injectors, and others. The pre-filled syringes are the dominating segment. Adoption of self-injecting parental devices and support for the pre-filled syringes from the government by providing funds also makes this segment dominating.

Based on indications, the multiple sclerosis is expected to dominate the global autoimmune disorders drug delivery devices market over the forecast period due to proactive support by the government in R&D field

Based on indications, the global autoimmune disorders drug delivery devices market has been segmented into psoriasis, multiple sclerosis, inflammatory bowel diseases, rheumatoid arthritis, systemic lupus erythematosus, and others. Multiple sclerosis is the dominating sub-segment due to the number of ongoing clinical trials focused on novel drug delivery devices using antibodies and the increasing prevalence of multiple sclerosis.

Based on end-users, hospitals segment is expected to grow at the highest CAGR during the forecast period due to increasing preference for hospital

Based on end-users, the global market is segmented into hospitals & clinics, and home care settings. Hospitals & clinics segment is witnessing significant growth during the forecast period. Hospital & clinics segment dominates the market due to favorable reimbursement and increased government support to strengthen government hospitals. 

Geographically, North America accounted for the largest share of the global autoimmune disorders drug delivery devices market

North America accounted for the largest share of the market in 2020 and is expected to maintain its dominance during the forecast period. This can be attributed to the substantial investment in research and development activities carried out in the healthcare sector. This factor supports the growth of the autoimmune disorders drug delivery devices market in North America.

In addition, favorable government initiatives to support innovations in the biopharmaceutical and biosimilars industries in this region that accelerate the growth of the autoimmune disorders drug delivery devices market. Europe region is expected to be followed closely by the North America region and is expected to witness significant growth during the forecast period. This is due to an increasing number of patients and developed healthcare infrastructure in the region.

The report also provides an in-depth analysis of the global autoimmune disorders drug delivery devices market dynamics such as drivers, restraints, opportunities, and challenges

Drivers

  • Rising prevalence of autoimmune disorders
  • Advancement in technologies
  • Upgradation of bio-pharmaceutical and bio-similar market
  • Availability of devices at reasonable rate

Restraints

  • Replacement for drug delivery system
  • Strict government regulations

Opportunities

  • Individualized treatment
  • Increasing investment by key-players

Challenges

  • Complications associated with products recall

COVID-19 Impact on the Global Autoimmune Disorders Drug Delivery Devices Market Analysis

Outbreak of COVID-19 has highly affected the industries in terms of growth, economy, health, and mental well-being of every individual. In this challenging situation, every industry is trying to give the best services in terms of quality and safety. Healthcare sector has been highly affected by the COVID outbreak. However, the targeted market has not been much affected due to the corona virus.

However, the funding and focus on research and development have been distracted due to this pandemic is the restraining factor for the growth of the autoimmune disorders drug delivery system market.

The report also provides in-depth analysis of key trends in global autoimmune disorders drug delivery devices market

  • Rising expenditure on research and development to catalyze the advancement of autoimmune disorders drug delivery devices
  • Increase adaptation of self-injecting parental devices

The report also provides in-depth analysis of recent news developments and investments

  • In Jan 2020, Bristol Myers Squibb announced the launch of Zeposia. It is the lowest price drug for the Multiple Sclerosis.
  • In 2019, Philips and Medisize has announced to manufacture a wearable drug and device combination product for leading biotechnology player present in the autoimmune disorders drug delivery devices market.

Company Profiles and Competitive Intelligence

The key players operating in the global autoimmune disorders drug delivery devices market are:

  • GlaxoSmithKline plc.
  • Amgen Inc.
  • Bayer AG 
  • Bristol- Mayers Squibb Company
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly & Company
  • Biogen Inc.
  • Sanofi S.A.
  • Merck KGaA.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • UCB Pharma SA.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Aptar Pharma
  • SMC Ltd.
  • Siemens Healthineers
  • Beckman Coulter, Inc.
  • EUROIMMUN AG.
  • Crescendo Bioscience

The unique insights provided by this report also includes the following:

  • In-Depth Value Chain Analysis
  • Opportunity Mapping
  • Sector Snapshot
  • Key Players Positioning Matrix
  • Regulatory Scenario
  • Strategies Adopted-Benchmarking Heat Map
  • Market Trends
  • COVID-19 Impact Analysis
  • Product Comparison
  • Pre & Post COVID 19 Impact On The Global Autoimmune Disorders Drug Delivery Devices Market 
  • Competitive Landscape

Frequently Asked Questions (FAQs)

What is the size of global market?

The global autoimmune disorders drug delivery devices market is estimated to be USD 2.7 Bn in 2020 and is expected to reach USD 7.3 Bn by 2027.

What is the estimated market growth rate of global market?

The global market is estimated to grow at a compound annual growth rate (CAGR) of 15.0% during the forecast period.

Which region accounted for the largest share in global autoimmune disorders drug delivery devices market?

North America accounted the largest share in global market.

What is the factor that hampers the growth of market?

Strict government regulation and availability of alternative drug delivery devices for the treatment of autoimmune disorders are the hampering factor for the growth of the market.

What’s are the major driving factors for the growth of global market?

Rising prevalence of autoimmune disorders is the major driving factors for the growth of the global market.

Which is the base year provided in the report of global autoimmune disorders drug delivery devices market?

The 2020 is the base year provided in the report of global market.

Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

  1. Introduction
    1. Product Outline
    2. What is Autoimmune Disorders Drug Delivery Devices?
    3. Different Types of Autoimmune Disorders Drug Delivery Devices
    4. Supply Chain Analysis
    5. COVID -19 Impact
    6. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Threats
  2. Regulatory Landscape for Global Autoimmune Disorders Drug Delivery Devices Market 
    1. Regulations and Standards
  3. Global Autoimmune Disorders Drug Delivery Devices Market by Product
    1. Pre-filled Syringes
    2. Pen Injectors
    3. Vials
    4. Auto-Injectors
    5. Others
  4. Global Autoimmune Disorders Drug Delivery Devices Market by Indications
    1. Psoriasis
    2. Multiple Sclerosis
    3. Inflammatory Bowel Diseases
    4. Rheumatoid Arthritis
    5. Systemic Lupus Erythematosus
    6. Others
  5. Global Autoimmune Disorders Drug Delivery Devices Market by End-Users
    1. Hospitals & Clinics
    2. Home Care Settings
  6. Regional Analysis
    1. North America
      1. US
      2. Canada
    2. Europe
      1. Germany
      2. UK
      3. France
      4. Italy
      5. Spain
      6. Rest Of Europe
    3. Asia Pacific
      1. China
      2. India
      3. Japan
      4. Rest Of Asia Pacific
    4. Middle East and Africa (MEA)
      1. South Africa
      2. Rest of MEA
    5. South America
      1. Mexico
      2. Brazil
      3. Rest of South America
  7. Key Strategic Insights
    1. Emerging Technologies
    2. Opportunity Mapping
    3. Critical Success Factors
    4. Consumer Preferences
  8. Key Market Trends / Recent Developments
  9. Competitive Scenario
    1. Competitive Strategies of Key Players
      1. Mergers and Acquisitions
      2. Investments
      3. Joint Ventures
    2. Ranking of Key Players
  10. Key Global Players
    1. GlaxoSmithKline plc.
    2. Amgen Inc.
    3. Bayer AG         
    4. Bristol- Mayers Squibb Company
    5. AbbVie Inc.
    6. F. Hoffmann-La Roche Ltd.
    7. Eli Lilly & Company
    8. Biogen Inc.
    9. Sanofi S.A.
    10. Merck KGaA.
    11. Johnson & Johnson Services, Inc.
    12. Novartis AG
    13. UCB Pharma SA.
    14. Teva Pharmaceutical Industries Ltd.
    15. Takeda Pharmaceutical Company Limited

Choose License
Buy Now
Why Choose AllTheResearch?
  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on “Quadrant Positioning” of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports. Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.


Quick Inquiry
Follow Us
Choose License
Buy Now